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INTRODUCTION
In Act 3, scene 1 of Shakespeare’s Hamlet, the famous phrase 
“To be or not to be, that is the question” is uttered. In the con-
text of this review, decisions in the bone marrow “to be or not to 
be” an eosinophil, and to “survive or not survive” are among 
the questions that will be addressed. Their role in homeostasis 
and in inflammation and immunity will also be covered. By ne-
cessity, some of the data relevant to these topics will be derived 
from in vitro studies and animal (mostly murine) studies, but 
whenever possible, human findings will be highlighted.
Development of eosinophils in the bone marrow (Fig. 1)
Eosinophils are produced in the bone marrow from multipo-
tent hematopoietic stem cells. Hematopoietic differentiation 
involves the commitment of multipotent progenitors to a given 
lineage, followed by the maturation of the committed cells. 
From these stem cells, the myeloid lineage allows the develop-
ment of the myeloblast with shared properties of basophils and 
eosinophils, and then into a separate eosinophil lineage.
1 Each 
of the steps that ultimately lead to mature eosinophils is under 
the fine regulation of soluble mediators and transcription fac-
tors.
Several transcription factors are involved in eosinophilic lin-
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eage. Forced expression of the transcription C/EBP members 
(CCAAT/enhancer-binding protein family) in progenitor cells 
induces myeloid and eosinophil differentiation.
2 PU.1, an ETS 
transcription factor family member, is only expressed in he-
matopoietic cells. At an early time point of the differentiation, 
PU.1 is involved in the transition between lymphoid and myel-
oid lineage. PU.1 expression level determines the fate of the cell 
and is necessary for dictating monocyte/macrophage and den-
dritic cell commitment and differentiation, as well as for neu-
trophil differentiation. In addition, high levels of PU.1 lead to an 
increase in myeloid differentiation.
3 In most cells, PU.1 antago-
nizes GATA-1 (a zinc finger family member), the latter of which 
has synergistic activity in regulating eosinophil lineage specifi-
cation and eosinophil granule protein transcription.
4 The inter-
feron consensus sequence binding protein (ICSBP) is also a key 
transcription factor for eosinophils and is demonstrated by a 
loss of eosinophils in ICSBP-deficient mice.
5 Of these transcrip-
tion factors, GATA-1 is clearly the most important for eosino-
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phil lineage specification, based on loss of the eosinophil lin-
eage in mice harboring a targeted deletion of the high affinity 
GATA-binding site in the GATA-1 promoter,
6 and based on eo-
sinophil differentiation experiments in vitro.
7
Cytokines are indispensable for hematopoietic cell develop-
ment, differentiation and maturation. Located on chromosome 
5q31, IL-3, IL-5, and granulocyte/macrophage-colony stimu-
lating factor (GM-CSF) are cytokines that are particularly im-
portant in regulating eosinophil development.
8 These “eosino-
philopoietins” likely provide permissive proliferative and differ-
entiation signals following the instructive signals specified by 
the transcription factors GATA-1, PU.1, and C/EBPs. IL-3 and 
GM-CSF also induce the differentiation of other myeloid cells 
such as the mast cell, but IL-3, GM-CSF and IL-5 synergize to-
ward the differentiation of eosinophils. Of these three cytok-
ines, IL-5 is the most specific to the eosinophil lineage and is re-
sponsible for selective terminal differentiation of eosinophils.
9 
IL-5 also stimulates the release of eosinophils from the bone 
marrow into the peripheral circulation.
10 The critical role of IL-5 
in regulating eosinophils in humans has been demonstrated in 
several clinical trials with humanized anti-IL-5 antibodies (me-
polizumab and reslizumab), currently a non-FDA approved 
drug, which dramatically lowers eosinophil levels in the blood 
in part by preventing eosinophil maturation in the bone mar-
row with arrest at the myelocyte and metamyelocyte stages.
11,12
Emigration from the marrow and lifespan of eosinophils in the 
circulation and tissues
The life cycle of the eosinophil may be divided into bone mar-
row, blood, and tissue phases. Although the eosinophil is a 
formed element of the peripheral circulation, it is primarily a 
tissue-dwelling cell. In humans the tissue eosinophil/blood ra-
tio is about 100:1.
14 Furthermore, eosinophils tend to reside in 
those tissues where the epithelial surfaces are exposed to the 
external environment (gut); mast cells primarily reside in these 
tissues as well. Thus, eosinophils are considered merely to “pass 
through” the circulation en route to the tissues.
15
Once the eosinophil has entered the blood, it has a short half-
life, ranging from 8 to 18 hours. After circulating in the blood, 
eosinophils migrate into the tissues, probably by diapedesis at 
endothelial intercellular junctions
4 by a mechanism involving 
cytokines and adhesion molecules. Under normal conditions, 
once eosinophils enter the tissues, most do not recirculate. The 
tissue life span of eosinophils ranges from 2 to 5 days, depend-
ing partly on the tissue studied. However, cytokines increase 
eosinophil survival in vitro to 14 days or longer; thus, they likely 
Fig. 1.  From the hematopoietic stem cell to the mature eosinophil.
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also prolong eosinophil survival in vivo.
15
Under baseline conditions, most eosinophils traffic into the 
gastrointestinal tract where they normally reside within the 
lamina propria of all segments except the esophagus, where 
there are normally zero eosinophils.
16 The gastrointestinal eo-
sinophil is the predominant population of eosinophils. Under 
baseline conditions, eosinophil levels in the gastrointestinal 
tract occur independently of lymphocytes and enteric flora, in-
dicating unique regulation compared with other leukocytes.
16 
Indeed, the recruitment of gastrointestinal eosinophils is regu-
lated by the constitutive expression of eotaxin-1 (CCL11), dem-
onstrated by the marked decrease of this population of eosino-
phils in eotaxin-1-deficient mice.
17 The importance of eotaxin-1 
in regulating the baseline level of eosinophils is reinforced by 
the observation that mice with a targeted deletion of CCR3 (but 
not eotaxin-2 (CCL24)-deficient mice) also have a deficiency in 
gastrointestinal eosinophils.
17 In addition to trafficking into the 
gastrointestinal tract, eosinophils home into the thymus, mam-
mary gland, and uterus under homeostatic conditions, also un-
der the regulation of eotaxin-1.
18 Of note, trafficking into the 
uterus is regulated by estrogen, as eosinophil and eotaxin-1 lev-
els cycle along with estrus.
19
While IL-5 does not appear to be nearly as important as chemok-
ines for eosinophil recruitment, locally produced IL-5 does have 
an important function in increasing the survival of eosinophils 
once they have reached the tissues.
Role of eosinophils in host defense and diseases
Infection
1. Helminths
Eosinophil function has primarily been associated with its 
role in host defense against parasitic infection. Angiostrongylia-
sis costaricensis, Ascariasis, Hookworm infection, Strongyloidia-
sis, Trichinosis, Schistosomiasis, Clonorchiasis, and Paragonimi-
asis usually cause marked eosinophilia (more than 3,000/μL). 
The level of eosinophilia parallels the magnitude and extent of 
tissue invasion by helminth larvae or adults.
20
Several studies using helminth infection models have evaluat-
ed the propensity of eosinophils to: (1) mediate antibody (or 
complement) dependent cellular toxicity against helminths in 
vitro,
21 (2) degranulate in the local vicinity of damaged parasites 
in vivo during helminthic infections, and (3) be required for 
parasite clearance in experimental parasite infected mice that 
have been depleted of eosinophils by IL-5 neutralization and/
or gene targeting.
22
Murine studies are particularly problematic because mice are 
not the natural hosts of many of the experimental parasites; 
nevertheless, in some primary infection models, a role for IL-5 
in protective immunity has been suggested following infection 
with Strongyloides venezuelensis, Strongyloides ratti, Nippostrongy-
lus brasiliensis, and Heligmosomoides polygyrus.
22 These mu-
rine in vivo studies need to be interpreted with caution because 
IL-5 neutralization may have effects on other IL-5 receptor-
bearing cells (including murine B cells, unlike its biology in hu-
mans).
9 Other approaches, including the analysis of CCR3- and 
eotaxin-1-deficient mice, have recently demonstrated a role for 
eosinophils in the encystment of larvae in Trichinella spiralis 
and in controlling the Brugia malayi microfilariae, respective-
ly.
23 The role of eosinophils in host defense against helminthic 
parasites in Schistosoma mansoni infection model has been 
studied in the two eosinophil lineage ablation mouse lines (Dd-
blGATA and PHIL). They found that eosinophil ablation had no 
effect on worm burden or on egg deposition, indicating that in 
mice, eosinophils are not necessary for immunity to this organ-
ism.
24 Thus, although the debate continues, it seems likely that 
eosinophils participate in the protective immunity against se-
lected helminths.
2. Viruses
Eosinophil granule proteins are known for their ribonuclease 
activity (such as human eosinophil cationic protein (ECP, RNase 
3) and eosinophil-derived neurotoxin (EDN, RNase 2), and at 
least 11 eosinophil associated ribonucleases (EAR) orthologs in 
mice) and have been shown to degrade single-stranded RNA-
containing viruses.
25 Interestingly, it has recently been shown 
that viruses (parainfluenza virus, respiratory syncytial virus 
(RSV), or rhinovirus) induce the release of eosinophil peroxi-
dase (EPO) by eosinophils when co-incubated in the presence 
of antigen-presenting cells and T cells.
26 In fact, ECP and EDN 
are the most divergent coding sequences in the entire human 
genome (compared with other primates).
25 Despite their diver-
gence, they have conserved ribonuclease activity across spe-
cies, strongly implicating evolutionary pressure to preserve this 
critical enzymatic activity. Eosinophils may also have a protec-
tive role in other infections, especially against RNA viruses, such 
as RSV and the related natural rodent pathogen, pneumonia vi-
rus of mice (PVM), in vivo.
25, 27 Eosinophils are recruited and 
degranulate in lung tissue in response to human RSV (hRSV) 
infection.
28 Experiments performed in vitro and in several dif-
ferent mouse models suggest mechanisms underlying this as-
pect of eosinophil recruitment,
29 and provide evidence consis-
tent with a role for these cells in promoting viral clearance.
30 
Paradoxically, an in vitro study has shown that eosinophils may 
be an important reservoir for the HIV-1 virus in vivo.
31
3. Fungus
Recent investigation has focused on the role of eosinophils in 
fungal infections. Indeed, eosinophils release their cytotoxic 
granule proteins into the extracellular milieu and onto the sur-
face of fungal organisms and kill fungi in a contact-dependent 
manner.
32 Eosinophils use their versatile b2-integrin molecule, 
CD11b, to adhere to a major cell wall component, b-glucan, but 
eosinophils do not express other common fungal receptors, 
such as dectin-1 and lactosylceramide. The I-domain of CD11b Allergy Asthma Immunol Res. 2010 April;2(2):87-101.  doi: 10.4168/aair.2010.2.2.87
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is distinctively involved in eosinophil interaction with b-glucan. 
Interestingly, eosinophils do not react with chitin, another fun-
gal cell wall component, even though chitin is a strong Th2 
stimulus.
32 Fungal protease activity induces cellular activation 
and eosinophil-derived neurotoxin release in human eosino-
phils through protease-activated receptors (PAR-2),
33 Nonpatho-
genic, environmental fungi induce activation and degranula-
tion of human eosinophils.
34 Challenge in the lung with Asper-
gillus fumigatus or OVA revealed marked induction of murine 
eotaxin-2 mRNA.
35
4. Bacteria
Eosinophils rapidly release mitochondrial DNA in response to 
exposure to bacteria, C5a or CCR3 ligands. The traps contain 
the granule protein ECP and MBP, and display antimicrobial 
activity.
36 In the extracellular space, the mitochondrial DNA 
and the granule proteins form extracellular structures that bind 
and kill bacteria both in vitro and under inflammatory condi-
tions in vivo. After cecal ligation and puncture, IL-5-transgenic, 
but not wild type, mice show intestinal eosinophil infiltration 
and extracellular DNA deposition in association with protec-
tion against microbial sepsis. This data suggests a previously 
undescribed mechanism of eosinophil-mediated innate im-
mune responses that might be crucial for maintaining the in-
testinal barrier function after inflammation-associated epithe-
lial cell damage, preventing the host from uncontrolled inva-
sion of bacteria.
Allergic diseases
1. Asthma
Increases of eosinophils in the tissues, blood, and bone mar-
row are a hallmark of most asthma phenotypes and, in general, 
elevated numbers correlate with disease severity (although 
“non-eosinophilic/non-neutrophilic” asthma is characteristic 
of bacterial, viral, and pollutant triggers).
37 This has led to the 
hypothesis that the eosinophil is a central effector cell responsi-
ble for ongoing airway inflammation. Granule proteins, such as 
MBP, have been found in bronchoalveolar lavage fluid from pa-
tients with asthma in sufficient concentrations to induce cyto-
toxicity of a variety of host tissues including respiratory epitheli-
al cells in vitro.
38 MBP has been indirectly involved in airway 
hyperreactivity (AHR) due to its ability to directly increase 
smooth muscle reactivity by causing dysfunction of vagal mus-
carinic M2 receptors.
39 In addition to its effect on tissue, MBP 
can trigger the degranulation of mast cells and basophils that 
may also be involved in disease pathogenesis.
38 Eosinophils 
generate cysteinyl leukotrienes (cysLTs) that may lead to in-
creased vascular permeability, mucus secretion, and smooth 
muscle constriction.
40 Indeed, inhibitors of cysLTs are effective 
therapeutic agents for the treatment of allergic airway disease. 
Thus, the cell has the potential to cause damage to the airway 
mucosa and associated nerves through the release of granule-
associated basic proteins (which damage nerves and epithelial 
cells), lipid mediators (which cause bronchoconstriction and 
mucus hypersecretion), and reactive oxygen species (which 
generally injure mucosal cells).
Blood eosinophils from patients with asthma have a number 
of phenotypic alterations, particularly in relation to their adhe-
sive properties. Thus airway eosinophils recovered after antigen 
challenge have enhanced adhesion to VCAM-1 (CD106) and 
other ligands including albumin, ICAM-1 (CD54), fibrinogen, 
and vitronectin. These hyperadhesive properties seem to be 
mediated by up-regulated and activated aMb2 (CD11b/18).
41 
Eosinophils in asthmatics also have increased expression of 
collagen receptors a1b1 and a2b1 integrins.
42
More attention is now given to a possible role for the eosino-
phil in repair and remodeling processes since there is a well-
documented association of tissue eosinophilia and eosinophil 
degranulation with certain fibrotic syndromes. The cell is the 
source of several fibrogenic and growth factors, including trans-
forming growth factor (TGF)-b, fibroblast growth factor (FGF)-
2, vascular endothelial growth factor (VEGF), matrix metallo-
protease (MMP)-9, IL-1b, IL-13, and IL-17. Studies in humans 
using anti-IL-5 antibodies also support a role for eosinophils in 
events surrounding deposition of certain matrix proteins with-
in the reticular basement membrane.
43 When asthmatics were 
given three infusions of anti-IL-5 (mepolizumab) this produced 
about a 90% reduction in blood and bronchial lavage eosino-
phils but only 55% reduction in bronchial mucosal eosino-
phils,
44 even though several matrix proteins were dramatically 
reduced by anti-IL-5 treatment.
45
In order to provide definitive evidence that eosinophils are 
key cells in airway remodeling, more effective strategies are re-
quired to deplete tissue eosinophils.
46,47 Even in animal models 
of asthma there was residual tissue eosinophilia in the airways 
after anti-IL-5 administration.
48 In a mouse model, ablation of 
eotaxin chemokines prevented antigen induced pulmonary eo-
sinophilia
49 and antagonism of CCR3 reduced eosinophil num-
bers accompanied by a diminution in asthma pathology.
50
There is no firm evidence that eosinophils or their products 
are directly causative in AHR in clinical asthma. The correlation 
between blood and tissue eosinophils and the degree of AHR is 
generally weak or nonexistent. While observed in humans, eo-
sinophil degranulation is not always consistent in murine mod-
els.
51 Elevated levels of blood and/or lung eosinophils are not 
constitutively associated with lung changes in studies with 
transgenic mice over-expressing IL-5 (in T cells, lung epithelial 
cells, or enterocytes).
52,53 Neutralization of IL-5 or IL-5 deficient 
mice, has reduced lung eosinophilia in allergen-challenged 
lungs,
54 but this reduction is not total and does not always cor-
relate with lung function (AHR).
55 For example, antigen-in-
duced AHR occurs in allergic IL-5-deficient BALB/c mice but 
not in IL-5-deficient mice of the C57BL/6 strain.
56 A modest ef-
fect is seen in human asthma studies using anti-IL-5 antibod-Allergy Asthma Immunol Res. 2010 April;2(2):87-101.  doi: 10.4168/aair.2010.2.2.87
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ies. Patients with mild to moderate asthma were shown to have 
decreased circulating and sputum eosinophil levels;
12 however, 
no clinical benefit (e.g., improvement in FEV1) was demon-
strated. In subsequent studies, however, mepolizumab therapy 
reduced exacerbations and improved AQLQ scores in patients 
with refractory eosinophilic asthma,
57 It also reduced the num-
ber of blood and sputum eosinophils and allowed prednisone 
sparing in patients who had asthma with sputum eosinophilia 
despite prednisone treatment.
58 Indeed, clinical studies have 
shown that AHR correlates with mast cell localization near pul-
monary nerves, whereas pulmonary eosinophilia relates more 
strongly with chronic cough.
59
2. Atopic dermatitis
In spite of the progress regarding the description of immuno-
logical phenomena associated with atopic dermatitis (AD), the 
pathogenesis of this disease still remains unclear. The presence 
of eosinophils or their granules in the inflammatory infiltrate of 
AD has long been established. Eosinophil numbers as well as 
eosinophil granule protein levels in peripheral blood are elevat-
ed in most AD patients and appear to correlate with disease ac-
tivity. Interestingly, abundant MBP-positive staining in the skin 
of AD patients occurs, even in the absence of eosinophils.
60 
These observations indicate a role for eosinophils in the patho-
genesis of AD. Furthermore, AD is associated with increased 
production of Th2 cytokines including IL-5 and IL-4. In AD, 
IL-5 would specifically act on eosinophils, resulting in acceler-
ated eosinophilopoiesis, cell activation, and delayed apoptosis, 
and IL-4 would be responsible for the Th2 response and eo-
sinophil specific chemokine production. Therefore, IL-5 is an 
interesting target for experimental therapy in this inflammatory 
disorder of the skin. Such studies might result in new insights 
into the pathogenic role of eosinophils in AD.
Gastrointestinal (GI) disorders
While present in multiple tissues, only GI eosinophils are as-
sociated with marked eosinophil degranulation.
61 In healthy 
patients or normal mice, eosinophils are present in the lamina 
propria throughout the GI tract from the stomach to the colon.
61 
However, eosinophils are not normally found in Peyers patch-
es, or intraepithelial locations.
62 The accumulation of eosino-
phils in the GI tract is a common feature of numerous disorders 
such as drug reactions, helminth infections, gastroesophageal 
reflux disease, hypereosinophilic syndrome (HES), eosino-
philic gastroenteritis (EGE), allergic colitis and inflammatory 
bowel disease.
62 Primary eosinophil-associated gastrointestinal 
diseases (EGIDs) such as eosinophilic esophagitis (EE), eosino-
philic gastritis (EG), EGE, eosinophilic enteritis, and eosino-
philic colitis are defined as disorders that mainly affect the gas-
trointestinal tract with eosinophil-rich inflammation in the ab-
sence of known causes of eosinophilia (e.g., drug reactions, par-
asitic infections, malignancy). These are hypersensitivity disor-
ders that lie in the middle of a spectrum ranging from anaphy-
laxis to Celiac disease.
62
Interestingly, the intestine of eotaxin-1 deficient mice is al-
most completely devoid of eosinophils, and similar results were 
observed in CCR3 deficient mice, which shows a decreased eo-
sinophil level at baseline, in the jejunum.
63
While absent in the normal esophagus, eosinophils markedly 
accumulate in the esophagus of EE patients. A minimum of 15 
eosinophils per high power field is now used as pathological 
criteria for EE.
64 Murine models have demonstrated that IL-5 
maintains the systemic eosinophil levels needed for esopha-
geal eosinophilia accumulation.
16 Substantial evidence is accu-
mulating that human EE is also associated with a Th2 type im-
mune response and local or systemic Th2 cytokine overproduc-
tion; IL-5 mRNA expression is induced in the biopsies of EE pa-
tients compared to healthy controls,
65 and anti-IL-5 may be ef-
fective in some but not all patients with EE.
66, 67 In human EE, 
eotaxin-3 (CCL26) expression strongly correlates with eosino-
phil numbers.
68
A large percentage (~10%) of patients suffering from EGID 
have an immediate family member with EGID.
69 Additionally, 
several lines of evidence support an allergic etiology: (i) about 
75% of patients with EGID are atopic;
70 (ii) the severity of dis-
ease can sometimes be reversed by institution of food elimina-
tion diet;
70 and (iii) the common finding of mast cell degranula-
tion in tissue specimens.
71 Importantly, recent models of EGID 
support a potential allergic etiology for these disorders.
72 Inter-
estingly, despite the common finding of food-specific IgE in pa-
tients with EGID, food-induced anaphylactic responses only 
occur in a small minority of patients.
73 Thus, EGIDs have prop-
erties that fall between pure IgE-mediated food allergy and cell-
mediated hypersensitivity disorders (e.g., celiac disease).
73
Hypereosinophilic diseases
HES and chronic eosinophilic leukemia (CEL) are related he-
matological conditions characterized by sustained hypereosino-
philia (>1,500 eosinophils/μL). The term CEL is used when there 
is evidence that the disease is of clonal origin. A subset of pa-
tients with HES have a 800 kb interstitial deletion on chromo-
some 4q12 that results in the fusion of a gene of unknown func-
tion, Fip1-like1 (FIP1L1), with the platelet-derived growth fac-
tor receptor-a (PDGFRA).
74 Dysregulated tyrosine kinase activi-
ty by the FIP1L1-PDGFRA fusion gene has been identified as a 
cause of clonal HES, called FIP1L1-PDGFRA-positive CEL in 
humans. However, transplantation of FIP1L1-PDGFRA-trans-
duced hematopoietic stem cells/progenitors (HSC/Ps) into mice 
results in a chronic myelogenous leukemia-like disease, which 
does not resemble HES. Because a subgroup of patients with 
HES show T-cell-dependent IL-5 over-expression, whether the 
expression of the FIP1L1-PDGFRA fusion gene in the presence 
of transgenic T-cell IL-5 over-expression in mice induces HES-
like disease was studied. Mice that received a transplant of CD2-Allergy Asthma Immunol Res. 2010 April;2(2):87-101.  doi: 10.4168/aair.2010.2.2.87
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IL-5-transgenic FIP1L1-PDGFRA positive HSC/Ps (IL-5Tg-F/P) 
developed intense leukocytosis, strikingly high eosinophilia, 
and eosinophilic infiltration of non-hematopoietic as well as 
hematopoietic tissues, a phenotype resembling human HES. 
The disease phenotype was transferable to secondary transplant 
recipients, suggesting involvement of a short-term repopulat-
ing stem cell or an early myeloid progenitor. Induction of signif-
icant eosinophilia is, in this model, specific for FIP1L1-PDGFRA 
since expression of another fusion oncogene, p210-BCR/ABL, 
in the presence of IL-5 over-expression is characterized by a sig-
nificantly lower eosinophilia than IL-5Tg-F/P recipients. These 
results suggest that FIP1L1-PDGFRA fusion gene is not sufficient 
to induce a HES/CEL-like disease but requires a second event 
associated with IL-5 overexpression.
75 Finally, treatment with 
mepolizumab can result in corticosteroid-sparing for patients 
negative for FIP1L1-PDGFRA who have the hypereosinophilic 
syndrome.
76
PATHWAYS FOR MAINTAINING EOSINOPHIL SURVIVAL
IL-5 appears to be the most important and specific survival 
factor for eosinophils, at least within the human system.
77 Be-
sides IL-5, other important locally produced survival factors in-
clude GM-CSF and, perhaps to a lesser degree, IL-3, tumor ne-
crosis factor-a (TNF-a), interferon-g, leptin,
78 CD40 engage-
ment
79 and others.
IL-5/IL-3/GM-CSF receptor family
Both IL-3 and GM-CSF are pluripotent cytokines with activi-
ties on other hematopoietic lineages, whereas IL-5 is selective 
for the eosinophil lineage and plays a crucial role in driving 
committed eosinophil progenitor-cell proliferation, terminal 
differentiation, and post-mitotic priming and activation.
80
It has been appreciated for some time that IL-3, GM-CSF and 
IL-5 enhance eosinophil survival when cultured in vitro for 
weeks, and thus it might be that in vivo eosinophil persistence 
in the tissues may be prolonged in their presence. From the hu-
man IL-5 data and in animal models, the ability of eosinophils 
to survive and function in the tissue is becoming an important 
focus. The development and maturation of eosinophils can oc-
cur in situ in peripheral sites of inflammation containing pre-
existing increased tissue eosinophils. Eosinophil progenitors 
are released into the circulation to reach such tissue sites.
81 Eo-
sinophils can release GM-CSF in an autocrine fashion,
82 a cy-
tokine which is stored in association with eosinophil granules.
83 
Other eosinophil-derived and stored cytokines (e.g., IL-4,
84 IL-
13
85) and chemokines (e.g., RANTES (CCL5))
48 may further am-
plify the inflammatory milieu. Thus, the local self-production of 
such factors by eosinophils may be important in tissue eosino-
phil reactions beyond IL-5. Local fibroblasts and epithelial cells 
produce IL-5 and GM-CSF. Eosinophils may enhance their own 
survival by directly stimulating CD4+ T cells within tissue to 
produce IL-5. Nasal explants from atopic patients were shown 
to survive ex vivo using similar mechanisms to promote ex-
tramedullary eosinophil maturation and survival.
83 These, as 
well as lung explants of Brown-Norway rats, exhibited rapid (6 
hours) accumulation of MBP-positive cells after allergen chal-
lenge of the explants in vitro.
86 The major signaling pathway of 
these events is associated with IL-5 receptor ligation leading to 
phosphorylation of JAK-2 and Lyn kinases, decreased BAX trans-
location, and ultimately decreased apoptosis.
87 Additionally, 
GM-CSF appears to have a strong role in inhibiting eosinophil 
apoptosis at the tissue level. Autocrine GM-CSF stimulation of 
eosinophils bound to fibronectin, via 4 integrins, promoted eo-
sinophil survival for two weeks.
82 Eosinophils, when instilled 
into the trachea of IL-5 knockout mice, not only survive in the 
absence of IL-5, but in concert with CD4+ T cells, migrate back 
into lung, and reconstitute the asthma phenotype of wild-type 
antigen-challenged animals.
88 Overall, while IL-5 is essential in 
the maturation and differentiation of eosinophils in the bone 
marrow,
89 the recruitment to tissues and function within tissues 
may be IL-5-independent.
Tumor necrosis factor-a
Eosinophil apoptosis can be induced in response to specific 
ligands of the so-called ‘death receptors’ of the tumor necrosis 
factor (TNF) family.
90 Studies on the role of TNF-a in the induc-
tion of eosinophil apoptosis have yielded inconsistent results. 
Currently available data suggest that induction of apoptosis oc-
curs only under conditions in which nuclear factor-kB is sup-
pressed.
91 If this is not the case, TNF-a may even be anti-apop-
totic for eosinophils. For instance, TNF-a was shown to activate 
the p38 mitogen-activated protein (MAP) kinase pathway re-
sulting in delayed eosinophil apoptosis.
92 Moreover, the surviv-
al effect of TNF-a under in vitro conditions was suggested to be 
mediated via GM-CSF induction in eosinophils, via activation 
of both TNF receptors, TNF-RI and TNF-RII.
93 Both TNF-a and 
IL-1 interact synergistically with IL-4 and IL-13 to augment 
VCAM-1 expression as well as intercellular adhesion mole-
cule-1 (ICAM-1, CD54) expression.
94 Recent data suggest that 
TNF-a prolongs human eosinophil survival by activating both 
TNF receptor subtypes and NF-kB, but that the mechanism 
does not involve production of GM-CSF. Interestingly, gluco-
corticoids completely reversed TNF-a but not IL-5-afforded eo-
sinophil survival.
95 This would imply that the mechanism of 
TNF-a-induced eosinophil survival differs from that of IL-5. 
Glucocorticoids have been reported to inhibit NF-kB activa-
tion.
96 In contrast, IL-5 does not cause discernible activation of 
NF-kB.
97 This supports the idea that TNF-a induced eosinophil 
survival is mediated via activation of NF-kB pathway.
Interferons
In vitro interferon (IFN)-a, IFN-b and IFN-g each suppresses 
colony formation by both multipotential colony-forming units: Allergy Asthma Immunol Res. 2010 April;2(2):87-101.  doi: 10.4168/aair.2010.2.2.87
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granulocyte, erythroid, macrophage, and megakaryocyte and 
day 7 and 14 colony-forming unit granulocyte-macrophage.
98 
This effect is not dependent on the presence of monocytes, T or 
B lymphocytes, hence, IFNs appear able to block colony forma-
tion by a direct inhibitory effect on colony-forming cells. IFN-a 
may also act indirectly to reduce eosinophilia through its ability 
to up-regulate synthesis of IFN-g,
99 a proinflammatory product 
of Th1 CD4+ lymphocytes that inhibits differentiation of eo-
sinophils from IL-3- and IL-5-stimulated umbilical cord mono-
nuclear cells as well as their tissue migration.
100 Both IFN-a and 
IFN-g have complex effects on eosinophils. Both IFNs en-
hanced eosinophil viability in vitro, with IFN-g being more ef-
fective.
101 However, in cultures of human umbilical cord mono-
nuclear cells, eosinophil viability decreased markedly after a 
1-week culture with IFN-a or with IFN-g,
102 and the number of 
apoptotic eosinophils increased as well.
Leptin
Leptin is a survival cytokine for human eosinophils, a finding 
with potential pathologic relevance in allergic and parasitic dis-
eases.
78 Leptin activates both phosphatidylinositol-3-OH (PI3) 
kinase and MAP kinase signaling pathways, resulting in the in-
hibition of the mitochondrial death pathway.
103
CD40
Eosinophils have been shown to express the membrane re-
ceptor CD40, the ligation of which results in enhanced eosino-
phil survival as a consequence of autocrine GM-CSF release. 
Tissue eosinophils resident in nasal polyp tissue have been 
shown to have a high constitutive expression of CD40.
104 The li-
gand for CD40, CD40L, is expressed by CD4+ T cells that are 
also present in nasal polyp tissue, which suggests an intriguing 
potential for a further relationship between eosinophils and T 
cells. CD40 engagement also enhances eosinophil survival 
through induction of cellular inhibitor of apoptosis protein 2 (c-
IAP2) expression and suggests a role for this mechanism in al-
lergic inflammation.
79 CD40 was not expressed on freshly-iso-
lated blood eosinophils, but was seen following culture.
IL-33
IL-33 potently induces eosinophil adhesion and CD11b ex-
pression and enhances eosinophil survival, albeit not as effec-
tively as IL-5. The IL-33-ST2 pathway might be an important 
regulator of eosinophil biology in the pathogenesis of Th2-bi-
ased allergic diseases.
105
PASSIVE CELL DEATH AND APOPTOSIS
IL-5 and its signaling pathway
GM-CSF, IL-3 and IL-5 are cytokines important for eosinophil 
survival.
101 The signaling pathways involved in cytokine-afford-
ed eosinophil survival are complex and partly unknown. The 
receptors for IL-3 (CD123), IL-5 (CD125) and GM-CSF (CD116) 
each have unique a-chains but chare a common b-chain 
(CD131).
106 The b-chain is essential for signal transduction and 
explains the overlapping activities of these cytokines. Cytokine 
receptors depend on dimerization for their activation, and 
upon dimerization, multiple tyrosine residues in the b-chain 
become phosphorylated.
106 In general, the signaling events in-
clude the phosphorylation of tyrosine kinases, adapter proteins 
such as Shc and Grb-2, Ras-MAP kinase pathways, and janus 
kinase (Jak)-signal transducer and the activator of transcription 
(STAT) pathways (Fig. 2).
The intracellular pathways important in the inhibition of eo-
sinophil apoptosis and their subsequent enhanced survival by 
IL-3, GM-CSF and IL-5 include the Lyn, Jak2, Raf1 and MAP ki-
nases.
108 Indeed, intracellular levels of protein tyrosine phos-
phorylation appear to be vital in determining whether an eo-
sinophil will exhibit prolonged survival or undergo apoptosis, 
and a role for both tyrosine phosphorylation and the tyrosine 
kinase Lyn was recently demonstrated in Fas receptor-mediat-
ed apoptosis in eosinophils.
109 The picture is complicated fur-
ther by the observation that levels of intracellular reactive oxy-
gen species in human eosinophils also appear to be involved in 
regulating their apoptosis and that antioxidants blocked Fas-
mediated eosinophil death.
77
Mitogen-activated protein (MAP) kinase
MAP kinases are serine and threonine kinases, which can be 
activated by phosphorylation in kinase cascades. The members 
include extracellular-regulated kinase (ERK) 1, 2, 5 and 6, JNK/
SAPK, and various isoforms of p38.
110
p38 MAP kinase is constitutively activated in surviving eo-
sinophils, and when eosinophils are dying, it is de-activated in 
Fig. 2.  The intracellular signalling pathways of survival-prolonging cytokines 
IL-3, IL-5 and GM-CSF.
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those cells. Furthermore inhibition of p38 MAP kinase activity 
enhances spontaneous apoptosis.
92 These results suggest that 
p38 MAP kinase is involved in the signaling that supports eo-
sinophil survival. The factor(s) that initially lead to p38 activa-
tion in eosinophils currently remain unknown.
92 This leads to 
the interesting hypothesis that compounds that inhibit p38 
MAP kinase activity may reduce eosinophilia. In fact, this may 
be true as a p38 MAP kinase inhibitor, SB239063 has been 
shown to almost completely abolish lung eosinophilia in oval-
bumin-sensitized and challenged mice.
111 In contrast to p38 
MAP kinase, inhibition of ERK 1/2 activity seems not to alter 
the rate of spontaneous apoptosis in eosinophils.
92
Sodium salicylate has been reported to induce JNK and p38 
MAP kinase activation in human eosinophils as well as to in-
duce apoptosis, but the effects of sodium salicylate on apopto-
sis could not be reversed by inhibiting JNK and p38 with anti-
sense oligodeoxynucleotides or with the specific p38 MAP ki-
nase inhibitor SB203580,
112 thus suggesting that JNK and p38 
MAP kinase are not mediating sodium salicylate-induced eo-
sinophil apoptosis.
Caspases
Despite a great variety of available apoptotic stimuli, final 
changes in the dying cell are similar and many of the signaling 
events appear to converge into common mechanisms involv-
ing activation of cysteine-containing proteases that cleave their 
target proteins at specific aspartic acids (caspases) (Fig. 3). Cas-
pases are part of a family that so far comprise 14 members.
113 
They are present in the cells as inactive zymogens that must be 
cleaved to generate free catalytic subunits able to associate and 
form active heterotetramers.
The presence of caspases 3, 6, 7, 8 and 9 in eosinophils has 
been described and these caspases are associated with sponta-
neous eosinophil apoptosis.
115 The family of caspases can be di-
vided into two functional subgroups, the initiator and the exe-
cutioner caspases. Many apoptotic responses are initiated by 
activation of the initiator caspases-8 or -9. Initiator caspases ne-
cessitate special mechanisms of activation of zymogens. For in-
stance, caspase-8 can be activated following recruitment and 
clustering at multicomponent apoptosis-signaling complexes, 
resulting from ligation of cell surface molecules of the TNF re-
ceptor family, presumably by auto-processing of the zymogens 
according to the induced-proximity model.
116 Caspase-9 is acti-
vated by recruitment to Apaf-1 in the presence of ATP following 
release of cytochrome c from mitochondria.
117
Activation of either of these caspases can result in activation 
of executioner caspases such as caspase-3, leading eventually 
to apoptosis. Caspase-3 has been shown to be an important ef-
fector caspase in eosinophils following mitochondrial activa-
tion involving the Bcl-2 family protein Bax.
115
IL-5 prevents the caspase activation.
115 In one study, a cas-
pase-9 inhibitor blocked eosinophil apoptosis, confirming the 
view that mitochondria are involved in pro-apoptotic signaling 
in eosinophils.
118 In addition, broad-range caspase inhibitors 
also blocked eosinophil apoptosis, suggesting that caspases are 
indeed critical elements of the death machinery in eosinophils.
Bcl-2 family members
There have been several reports suggesting the involvement 
of members of the Bcl-2 family in the regulation of apoptosis 
that usually regulate the pro-apoptotic activity of mitochondria. 
This has been somewhat surprising since granulocytes have 
been described as cells with limited numbers of mitochon-
dria.
119 Recently published work, however, suggests that eosino-
phils contain small numbers of mitochondria, which are in-
volved in the induction of apoptosis.
118
Pro-apoptotic Bax molecules have been found to be expressed 
at high levels in eosinophils.
120 Moreover, eosinophil apoptosis 
was associated with translocation of cytosolic Bax into the out-
er membrane of mitochondria where it forms pores, allowing 
the release of pro-apoptotic factors such as cytochrome c.
115 
Clearly, high levels of Bax may contribute but may not be suffi-
cient to shorten the life span of eosinophils. The more proximal 
mechanisms that are responsible for Bax translocation to mito-
chondria in the absence of sufficient stimulation with survival 
cytokines remain to be determined.
Besides the pro-apoptotic Bax, eosinophils also express anti-
apoptotic members of the Bcl-2 family. For instance, Bcl-xL was 
shown to play an antiapoptotic role and was inducible by IL-5 
in eosinophils.
120 In contrast, Bcl-2 appears not to be expressed 
in eosinophils,
120 although there are some contrasting reports 
in the literature.
121 Fig. 3.  Various apoptotic stimuli lead to release of cytochrome.
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ACTIVE CELL DEATH AND APOPTOSIS
Fas
Fas (CD95, APO-1) is a cell surface receptor expressed on 
many cells including eosinophils, which mediates apoptosis 
when ligated by agonistic antibodies or its natural ligand FasL. 
It seems that IFN-g and TNF-a, both alone and synergistically, 
increase Fas receptor expression whereas IL-3/IL-5/GM-CSF 
do not modulate constitutive Fas receptor expression.
122 After 
treatment with Fas antibody, electron microscopy of eosino-
phils and gel electrophoresis of DNA extracted from eosino-
phils demonstrated changes consistent with apoptosis. These 
data demonstrate that Fas antigen can modify eosinophil sur-
vival by inducing apoptosis through a pathway that is, at least in 
part, independent of the survival-promoting effects of IL-5.
123 
Fas-mediated apoptosis in eosinophils can be only partially 
overcome by IL-5
124 and it can be further enhanced by gluco-
corticoids.
125 Cross-linking of Fas can induce eosinophil apop-
tosis in ex vivo conditions in nasal polyps
126 and in vivo in mouse 
lung.
127 Interestingly, blood and tissue eosinophils from some 
donors did not express functional Fas receptors, although Fas 
protein was normally expressed in these cells.
126
The signaling events induced by Fas in human eosinophils re-
main largely unknown. Ligation of Fas by agonistic antibody 
has been shown to result in tyrosine phosphorylation of several 
intracellular proteins and tyrosine kinase inhibitors lavendus-
tin A and genistein have been reported to block Fas-receptor-
induced cell death.
109 Lyn phosphorylation by Fas has been re-
ported, and decreases in the expression of Lyn by antisense 
technique resulted in partial reversal of Fas-induced cell death.
109 
Similarly, nitric oxide and cyclic adenosine 3’:5’-monophos-
phate (cAMP) and cGMP have been reported to reverse Fas-in-
duced eosinophil death.
128 Fas-ligation induces caspase-3 and 
-8 activation and loss of mitochondrial membrane potential 
(DYm). Interestingly, incubation of eosinophils with bongkre-
kic acid, an inhibitor of mitochondrial permeability transition 
pore opening, failed to modify Fas mediated loss in DYm and 
apoptosis, whereas caspase inhibitors Z-VAD fmk (broad spec-
trum), Z-IETD-fmk (caspase-8) and Z-DEVD-fmk (caspase-3) 
inhibited Fas-induced apoptosis indicating that caspase-3 and 
-8 might play a role, but loss of DYm is not involved in the sig-
naling by Fas in eosinophils.
124
Siglec-8 and Siglec-F
More recently, a selective mechanism for the induction of hu-
man eosinophil apoptosis by surface Siglec-8 (sialic acid-bind-
ing immunoglobulin-like lectin 8) cross-linking has been iden-
tified.
112 Siglec-8 is expressed on eosinophils but also on baso-
phils and mast cells. Such cross-linking in eosinophils leads to 
increased caspase 3 activity, which is an enzyme responsible 
for the degradation of cellular contents in the final stages of the 
apoptotic pathway leading to increased cell apoptosis. This is 
the case even in the presence of IL-5 and GM-CSF.
Mechanistic studies implicated both caspases and reactive 
oxygen species generation resulting in mitochondrial injury in 
this cell death. A paradigm has emerged that engagement of Si-
glec-8 activates the apoptotic pathway involving generation of 
reactive oxygen species leading to down-stream mitochondrial 
dysfunction and caspase cleavage before apoptotic death en-
sues.
129
One of the initially confusing observations regarding Siglec-8-
induced cell death was that unlike most other eosinophil death 
pathways that can be overridden by counterbalanced survival 
signals such as those provided by the cytokines IL-5 and GM-
CSF, Siglec-8-induced death was enhanced by these cytokines 
in that cells would die even more readily with even less of a Si-
glec-8 engagement signal.
112 These results were subsequently 
confirmed in eosinophils primed in vivo in humans following 
allergen bronchoprovocation, and primed cells no longer used 
caspases in the apoptosis process, instead relying exclusively 
on reactive oxygen species generation and mitochondrial inju-
ry.
130 Overall, these data suggest that activated eosinophils might 
be particularly susceptible to pharmacologic approaches that 
engage Siglec-8.
Intravenous immunoglobulin (IVIG) preparations that are 
used commercially contain autoantibodies to Siglec-8 at a high 
enough titer so as to also induce eosinophil apoptosis in vitro, 
especially in cytokine-primed cells.
131
Using IL-5 transgenic mice and Northern blotting, Siglec-E, -F 
and -G were all expressed at the mRNA level in mouse eosino-
phils, but patterns of expression were markedly increased in IL-5 
transgenic mice only for Siglec-F and Siglec-G.
132 Ultimately, it 
was not until antibodies were generated that this issue was com-
pletely resolved, and it is now clear that Siglec-G is expressed on 
B lymphocytes
133 while Siglec-F is most prominently expressed 
by mouse eosinophils and is considered the closest functional 
paralog to Siglec-8.
134
Systemic administration of two different types of Siglec-F an-
tibodies led to profound depletion of circulating and tissue eo-
sinophils. It appears that the reduction in eosinophil numbers 
in vivo was due to apoptosis based on ex vivo studies with blood 
samples from Siglec-F-treated mice, as well as studies in which 
eosinophils from IL-5 transgenic mice were exposed to Siglec-F 
antibody in vitro and characteristic changes indicative of apop-
tosis were seen.
135 Administration of anti-Siglec-F antibody in a 
mouse model of eosinophilic gastroenteritis significantly re-
duced levels of eosinophilic inflammation in the intestinal mu-
cosa and this was associated with reduced intestinal permea-
bility changes, normalization of intestinal villous crypt height, 
and restoration of weight gain,
136 Siglec-F antibody administra-
tion also significantly reduced levels of allergen-induced eo-
sinophilic airway inflammation and features of airway remod-
eling in a model of chronic mouse model of asthma, especially 
subepithelial fibrosis, by reducing the number of eosinophils Allergy Asthma Immunol Res. 2010 April;2(2):87-101.  doi: 10.4168/aair.2010.2.2.87
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and increasing the number of apoptotic eosinophils in lung and 
bone marrow.
137
TGF-b
TGF-b is a pleiotropic immunoregulatory cytokine that, for in-
stance, antagonizes the effects of IL-5 on eosinophils.
138 In ad-
dition to blocking the anti-apoptotic effects of IL-5, it also in-
hibits eosinophil degranulation and cytokine production. The 
mechanisms of this inhibitory effect of TGF-b are unknown. It 
has been demonstrated that TGF-b blocks tyrosine phosphory-
lation of Jak2 and Lyn tyrosine kinases.
139 Furthermore, it inhib-
its the activation of ERK MAP kinase and Stat1 nuclear factor. 
However, the signaling molecules mediating these effects have 
not yet been identified. Tyrosine phosphatases have been stud-
ied, but do not seem to be involved. It is possible that TGF-b ac-
tivates some of the newly described inhibitors of tyrosine kinas-
es, which subsequently mediate its inhibitory effects.
CD30
CD30, a member of the TNFR family, was originally identified 
as Ki-1, an antigen expressed on Reed-Sternberg cells in Hodg-
kin and non-Hodgkin lymphomas, particularly diffuse, large 
cell lymphoma and immunoblastic lymphoma.
140 TNFR family 
members, including two receptors for TNF, the nerve growth 
factor receptor, Fas, CD27, CD40, OX40, 4-1BB, TRAIL recep-
tors 1, 2, 3 and 4, as well as several soluble receptors of mam-
malian and viral origin, participate in cellular activation, induc-
tion of survival and/or apoptosis.
141
The roles of the nuclear receptor family in eosinophil functions 
have not yet been clarified. CD30 stimulation recently has been 
shown to cause eosinophil-specific apoptosis.
142 It has been fur-
ther reported that CD30 stimulation markedly induced Nur77 
and NOR1, NR4A nuclear receptor family, during eosinophil-
specific apoptosis.
143 However, CD30 stimulation did not alter 
Nurr1 expression in this system. Fas-signaling has also been 
shown to induce eosinophil apoptosis, but this effect is not eo-
sinophil-specific; nor were Nur77 or NOR1 induced before apop-
tosis under these circumstances. Gene expression of the NR4A 
nuclear receptor family and subsequent eosinophil apoptosis 
were down-regulated by a MAP kinase inhibitor, but not by a 
p38 inhibitor. ERK1/2 phosphorylation by MEK1/2 downstream 
of CD30 signaling and upstream of the nuclear receptor family 
may be involved in apoptosis, but there still is no information 
on events downstream of these nuclear receptors.
Corticosteroids
Glucocorticoids can cause a striking reduction in eosinophil 
numbers in vivo
144 and in their inhaled form remain the main-
stay of anti-inflammatory therapy in asthma.
145 Although the 
precise mechanism of action of steroids remains to be deter-
mined, glucocorticoids are likely to exert their effects on eosino-
phils by accelerating their apoptosis and engulfment by lung 
macrophages,
146 by inhibiting the production of survival-en-
hancing cytokines or both. It is now clear that glucocorticoids 
suppress the transcription of the IL-5 and other cytokine genes. 
This inhibition of transcription is the consequence of inhibition 
of the potent inflammatory transcription factor NF-kB (Fig. 4).
147
Eosinophils are highly sensitive to apoptosis induction by cor-
ticosteroids that can only be overcome by high concentrations 
of IL-5.
148 Previous work with eosinophils derived from both 
healthy and asymptomatic allergic individuals has demonstrat-
ed an involvement of caspase-3 and -8 in glucocorticoid-in-
duced apoptosis.
149 One recent study has demonstrated that in 
vitro corticosteroid treatment of eosinophils in nasal polyp tis-
sue sections enhanced their apoptosis induction,
150 suggesting 
that eosinophil apoptosis induction by glucocorticoids might 
be relevant to their anti-inflammatory effects in sinus disease. 
Interestingly, there is evidence that the bronchodilating b-ad-
renoreceptor agonists block the anti-apoptotic effects of corti-
costeroids on eosinophils,
151 which might have important im-
plications for the over-usage of b2-agonists in asthma therapy.
Lidocaine
Lidocaine and its analogues have been reported to inhibit IL-
5-mediated eosinophil survival. This inhibition cannot be over-
come by increasing concentrations of IL-5 and is not due to the 
blocking of Na+ channels by lidocaine.
152
IRp60/CD300a
IRp60/CD300a is an inhibitory receptor on eosinophil. Al-
though CD33 and p75/AIRM could inhibit proliferation of my-
eloid cell precursors, IRp60/CD300a could not suppress this 
feature, which suggests distinct functions for various inhibitory 
receptors.
153 CD300a/IRp60 can also inhibit eosinophil surviv-
al.
154 In contrast to Siglec-8, which induces eosinophil apopto-
sis, IRp60/CD300a inhibits survival signals delivered to eosino-
phils via the IL-3/IL-5/GM-CSF receptor bc.
154 Cross-linking ex-
Fig. 4.  Effects of glucocorticoids in eosinophilic inflammation.
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periments have revealed that upon IRp60/CD300a activation, 
JAK2, p38, and extracellular signal-regulated kinase 1/2 phos-
phorylation are inhibited, probably from the recruitment of 
SHP-1 and not SHP-2.
The different outcome of Siglec-8 activation (induction of apop-
tosis) as opposed to IRp60/CD300 activation (inhibition of sur-
vival signals) may be partially explained by the fact that Siglec-8 
contains both ITIM and ITSM motifs. ITSM motifs may recruit 
either inhibitory phosphatases such as SHP-1 and/or SHP-2 or 
activatory molecules such as slam-associated protein (SAP) and/
or 2-Ewing’s sarcoma-FLI activated transcript 2 (EAT-2).
155
CONCLUSIONS
Based on extensive research related to eosinophil biology, es-
pecially in mice and humans, have revealed much about the 
mechanisms involved in the birth, migration, accumulation, 
participation and ultimately the death of this cell. Acceleration 
of eosinophil apoptosis can be achieved by elimination of eo-
sinophil survival factors, and by promotion of death signals. 
These are no being exploited using new pharmacologic agents, 
including biologicals, in animals and humans, and in the pro-
cess of testing these drugs we are learning even more about the 
role of the eosinophil in a variety of disorders. Ultimately, the 
control of eosinophils may someday become another therapeu-
tic strategy in the treatment of asthma, HES, gastrointestinal eo-
sinophilic diseases and other related eosinophil disorders.
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